Organ protection beyond glycaemic control with SGLT2 inhibitors

Affiliations

¹ Renal Research Laboratory, Kolling Institute, University of Sydney, Royal North Shore Hospital, St. Leonards, Sydney, Australia.
² Renal Research Laboratory, Kolling Institute, University of Sydney, Royal North Shore Hospital, St. Leonards, Sydney, Australia. carol.pollock@sydney.edu.au.

Comment

Usha Panchapakesan et al. Nat Rev Nephrol. 2021 Apr.

. 2021 Apr;17(4):223-224.

doi: 10.1038/s41581-020-00373-4.

¹ Renal Research Laboratory, Kolling Institute, University of Sydney, Royal North Shore Hospital, St. Leonards, Sydney, Australia.
² Renal Research Laboratory, Kolling Institute, University of Sydney, Royal North Shore Hospital, St. Leonards, Sydney, Australia. carol.pollock@sydney.edu.au.

No abstract available

Comment on

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Packer M, et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. N Engl J Med. 2020. PMID: 32865377 Clinical Trial.
Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Clinical Trial.

1. Zinman, B. et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015). - DOI
1. Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017). - DOI
1. Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019). - DOI
1. Perkovic, V. et al. Canagliflozin and renal outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019). - DOI
1. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019). - DOI